All these mechanisms may be modulated by SGLT2-inhibition and are suggested to explain the nephroprotective action of SGLT2 inhibitors in diabetes, beyond the beneficial effect due to the reduction of hyperglycemia [15–20]. This evidence concerns the gene SLC5A2 and Hyperglycemia.